GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1029
- Registration Number
- NCT05559476
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT05553808
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 463
- Registration Number
- NCT05535972
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1080
- Registration Number
- NCT05496231
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
Phase 1
Recruiting
- Conditions
- Interventions
- Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full doseBiological: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full doseBiological: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low doseBiological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low doseDrug: PlaceboBiological: GSK's Meningococcal A, C, Y and W-135 conjugate vaccineOther: SalineBiological: Typhoid conjugate vaccine (TCV) low doseBiological: Typhoid conjugate vaccine (TCV) full doseCombination Product: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccineCombination Product: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 155
- Registration Number
- NCT05480800
- Locations
- 🇲🇼
GSK Investigational Site, Blantyre 3, Malawi
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 180
- Registration Number
- NCT05477186
- Locations
- 🇺🇸
Optimal Research Florida - Melbourne, Melbourne, Florida, United States
🇺🇸Research Centers of America - CenExcel, Hollywood, Florida, United States
🇺🇸Optimal Research Illinois - Peoria, Peoria, Illinois, United States
Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)
- Conditions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05448170
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Phase 1
Completed
- Conditions
- Interventions
- Biological: GSK4382276A Dose level 3Biological: GSK4382276A Dose level 11Biological: GSK4382276A Dose level 4Biological: GSK4382276A Dose level 2Biological: GSK4382276A Dose level 8Biological: GSK4382276A Dose level 10Biological: GSK4382276A Dose level 7Biological: GSK4382276A Dose level 9Combination Product: FDQ21A-NHCombination Product: FDQ22A-NHBiological: GSK4382276A Dose level 1Biological: GSK4382276A Dose level 6
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 324
- Registration Number
- NCT05446740
- Locations
- 🇪🇸
GSK Investigational Site, Majadahonda (Madrid), Spain
Food Effect Study of Linerixibat Tablets in Healthy Adult Participants
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT05435170
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT05424380
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
© Copyright 2024. All Rights Reserved by MedPath